| NCT ID | NCT05142787 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Endomagnetics Ltd. |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 224 participants |
| Start Date | 2023-03-02 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 224 participants in total. It began in 2023-03-02 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to provide prospective evidence that the Magseed Pro® marker /Sentimag® Gen3 system is safe and effective for marking A. suspicious/biopsy-proven positive axillary lymph nodes; and B. soft tissue lesions including cancer and pre-cancerous change in the breast
Eligibility Criteria
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study * Participant is aged 18 years or older at the time of consent. * Patients requiring breast lesion/axillary node marking and excision Exclusion Criteria:• Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period. A pregnancy test is required for all women of childbearing potential within 7 days before enrolment. * Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical trial or to comply with follow up requirements, or impact the scientific soundness of the clinical trial results * Known hypersensitivity to Nitinol * Subject has current active infection at the implantation site in the breast (per investigator discretion)
Contact & Investigator
Stefan Paepke, Dr
PRINCIPAL INVESTIGATOR
The technical university of Munich
Frequently Asked Questions
Who can join the NCT05142787 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05142787 currently recruiting?
Yes, NCT05142787 is actively recruiting participants. Contact the research team at mwomack@endomag.com for enrollment information.
Where is the NCT05142787 trial being conducted?
This trial is being conducted at Bottrop, Germany, Frankfurt, Germany, Munich, Germany, London, United Kingdom and 2 additional locations.
Who is sponsoring the NCT05142787 clinical trial?
NCT05142787 is sponsored by Endomagnetics Ltd.. The principal investigator is Stefan Paepke, Dr at The technical university of Munich. The trial plans to enroll 224 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.